跳到正文
原文
Endpoints News· @endpts · X·· 6 天前精选AI 评分72
AI 导读

默克(Merck KGaA)从中国和誉医药(Abbisko)授权引进的Pimjetmi获FDA批准,用于治疗罕见的非癌性关节肿瘤。该药由此成为又一款由中国创新药企授权出海并在美国获批的产品。

推荐理由

默克从中国和誉医药授权引进的药物获FDA批准,读者可据此观察中国创新药出海的授权与落地路径。

正文

Merck KGaA's Pimjetmi, licensed from China's Abbisko, won FDA approval for rare noncancerous joint tumors. https://endpoints.news/merck-kgaa-lands-fda-nod-for-joint-tumor-drug-it-licensed-from-abbisko/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

来源:Endpoints News · x.com